Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
Autologous CAR–T Cell Manufacturing: Current Standing and Future Directions
Genetic Engineering & Biotechnology News Following the approval of the first chimeric antigen receptor (CAR–T) cell construct by the FDA on August 30, 2017, industry stakeholders have been grappling with the many challenges of commercial-scale manufacturing of these types of therapies. |
PR Newswire (press release) |
Renova Therapeutics leadership speaking at Cell & Gene Therapy CEO forum and Boulder Peptide Symposium
PR Newswire (press release) Boston Biotech Conferences’ Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision-makers in cell therapy, gene therapy and regenerative medicine. Dr. Reich will be participating on a discussion panel on … |
EurekAlert (press release) |
A ‘social control’ system guarantees embryonic stem cell purity
EurekAlert (press release) What this discovery implies is that the pluripotent stem cell population is not pure, due to the appearance of primed cells with lower levels of Myc. Interestingly, when the cells divide, the daughter cells show a very strong tendency to conserve the … |
OncLive |
Duration of Upfront Immunotherapy for NSCLC
OncLive Everett Vokes, MD: We’ve covered a lot of the key studies. There are a lot of unanswered questions, of course. We covered where PD-L1-negative or low expressers fall into this, and we’re waiting for more data. Another issue is the duration of therapy … |